全文获取类型
收费全文 | 69831篇 |
免费 | 6190篇 |
国内免费 | 2767篇 |
专业分类
耳鼻咽喉 | 2116篇 |
儿科学 | 1656篇 |
妇产科学 | 1161篇 |
基础医学 | 6997篇 |
口腔科学 | 2223篇 |
临床医学 | 6697篇 |
内科学 | 7161篇 |
皮肤病学 | 828篇 |
神经病学 | 2894篇 |
特种医学 | 3739篇 |
外国民族医学 | 52篇 |
外科学 | 8495篇 |
综合类 | 11668篇 |
现状与发展 | 19篇 |
预防医学 | 1722篇 |
眼科学 | 759篇 |
药学 | 4555篇 |
48篇 | |
中国医学 | 1978篇 |
肿瘤学 | 14020篇 |
出版年
2024年 | 76篇 |
2023年 | 1002篇 |
2022年 | 1549篇 |
2021年 | 2924篇 |
2020年 | 2424篇 |
2019年 | 2230篇 |
2018年 | 2088篇 |
2017年 | 2348篇 |
2016年 | 2645篇 |
2015年 | 2798篇 |
2014年 | 4310篇 |
2013年 | 4345篇 |
2012年 | 3919篇 |
2011年 | 4344篇 |
2010年 | 3505篇 |
2009年 | 3541篇 |
2008年 | 3560篇 |
2007年 | 3854篇 |
2006年 | 3448篇 |
2005年 | 3090篇 |
2004年 | 2674篇 |
2003年 | 2231篇 |
2002年 | 2048篇 |
2001年 | 1841篇 |
2000年 | 1524篇 |
1999年 | 1390篇 |
1998年 | 1179篇 |
1997年 | 1113篇 |
1996年 | 840篇 |
1995年 | 866篇 |
1994年 | 729篇 |
1993年 | 592篇 |
1992年 | 493篇 |
1991年 | 411篇 |
1990年 | 328篇 |
1989年 | 331篇 |
1988年 | 312篇 |
1987年 | 265篇 |
1986年 | 213篇 |
1985年 | 261篇 |
1984年 | 228篇 |
1983年 | 147篇 |
1982年 | 191篇 |
1981年 | 157篇 |
1980年 | 108篇 |
1979年 | 101篇 |
1978年 | 69篇 |
1977年 | 53篇 |
1976年 | 44篇 |
1975年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
Marie Ohata Susumu Fujiwara Ai Yoshioka Hiroshi Nagai Shintaro Sugita Nozomi Yamano Yusuke Inoue Chikako Nishigori 《Pediatric dermatology》2019,36(6):997-998
Fibroblastic connective tissue nevus (FCTN) is a benign cutaneous mesenchymal lesion characterized by proliferation of CD34‐positive fibroblastic/myofibroblastic spindle‐shaped cells. We report a case of agminated FCTN on the right lower abdomen of a 1‐year‐old boy. 相似文献
72.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
73.
Lino Möhrmann Martina K. Zowada Hendrik Strakerjahn Christine Siegl Annette Kopp-Schneider Damir Krunic Dirk Strunk Martin Schneider Mark Kriegsmann Katharina Kriegsmann Friederike Herbst Claudia R. Ball Hanno Glimm Sebastian M. Dieter 《International journal of cancer. Journal international du cancer》2020,147(2):519-531
Disseminated tumor cells (dTCs) can frequently be detected in the bone marrow (BM) of colorectal cancer (CRC) patients, raising the possibility that the BM serves as a reservoir for metastatic tumor cells. Identification of dTCs in BM aspirates harbors the potential of assessing therapeutic outcome and directing therapy intensity with limited risk and effort. Still, the functional and prognostic relevance of dTCs is not fully established. We have previously shown that CRC cell clones can be traced to the BM of mice carrying patient-derived xenografts. However, cellular interactions, proliferative state and tumorigenicity of dTCs remain largely unknown. Here, we applied a coculture system modeling the microvascular niche and used immunofluorescence imaging of the murine BM to show that primary CRC cells migrate toward endothelial tubes. dTCs in the BM were rare, but detectable in mice with xenografts from most patient samples (8/10) predominantly at perivascular sites. Comparable to primary tumors, a substantial fraction of proliferating dTCs was detected in the BM. However, most dTCs were found as isolated cells, indicating that dividing dTCs rather separate than aggregate to metastatic clones—a phenomenon frequently observed in the microvascular niche model. Clonal tracking identified subsets of self-renewing tumor-initiating cells in the BM that formed tumors out of BM transplants, including one subset that did not drive primary tumor growth. Our results indicate an important role of the perivascular BM niche for CRC cell dissemination and show that dTCs can be a potential source for tumor relapse and tumor heterogeneity. 相似文献
74.
目的 探讨营养风险与腹膜后肿瘤患者住院时间的相关性。方法 采用回顾性研究,选取2012年1月至2018年12月四川大学华西医院血管外科新入院腹膜后肿瘤患者60例,采用营养风险筛查表评估患者营养风险,收集患者体质指数、围术期血红蛋白和白蛋白水平、住院天数、术后恶心呕吐发生情况、术后排气、排便时间和首次进食时间。采用单因素分析比较不同患者住院时间,采用多重线性逐步回归分析患者住院时间的影响因素。结果 纳入的60例腹膜后肿瘤患者中,40例患者(66.7%)术前存在营养风险,52例患者(86.7%)术后存在营养风险;单因素分析显示,患者术前、术后营养风险 (术前P<0.001,术后P=0.043)、术前白蛋白 (P=0.019)、术后血红蛋白 (P=0.019)、术后白蛋白(P=0.025) 水平以及术后恶心呕吐 (P=0.001) 均会影响患者的住院时间;患者住院时间与围术期营养风险筛查工具评分、术后首次进食时间、术后排气时间和排便时间具有相关性,且相关性强(r=0.759~0.770; P<0.01);多因素分析显示术前营养风险是腹膜后肿瘤患者住院时间的重要预测因素(β=0.399)。结论 术前营养风险是腹膜后肿瘤患者住院时间的预测因子。 相似文献
75.
Gregory N. Gan 《Expert opinion on investigational drugs》2016,25(10):1153-1166
Introduction: Cancer treatment is moving away from conventional cytotoxic drugs and towards agents that target specific proteins and mechanisms important to cancer development or survival. The Hedgehog Pathway (HhP) is a signal transduction pathway and its constitutive activation is tumorigenic in basal cell carcinoma (BCC). The HhP enables phenotypic flexibility, and channels tumor-stroma interactions. As a result, it is over-expressed in numerous cancers as well as in the tumor microenvironment and may represent a promising therapeutic target.Areas covered: In this article, we review the rationale for targeting HhP and its role as an oncogenic driver, in tumor epithelial-to-mesenchymal transition (EMT), and in the tumor microenvironment and describe the results of preclinical and clinical studies involving HhP inhibitors.Expert opinion: HhP activation plays an important role in both the tumor microenvironment and tumor EMT which can lead to treatment resistance for a number of different malignancies. In addition to standard use in BCC, several HhP inhibitors are in preclinical, early, and mid-stage clinical development for other solid and hematologic malignancies. 相似文献
76.
77.
Theresa M. Thole Joern Toedling Annika Sprüssel Sebastian Pfeil Larissa Savelyeva David Capper Clemens Messerschmidt Dieter Beule Stefanie Groeneveld-Krentz Cornelia Eckert Guido Gambara Anton G. Henssen Sabine Finkler Johannes H. Schulte Anja Sieber Nils Bluethgen Christian R. A. Regenbrecht Annette Künkele Marco Lodrini Angelika Eggert Hedwig E. Deubzer 《International journal of cancer. Journal international du cancer》2020,146(4):1031-1041
Accurate modeling of intratumor heterogeneity presents a bottleneck against drug testing. Flexibility in a preclinical platform is also desirable to support assessment of different endpoints. We established the model system, OHC-NB1, from a bone marrow metastasis from a patient diagnosed with MYCN-amplified neuroblastoma and performed whole-exome sequencing on the source metastasis and the different models and passages during model development (monolayer cell line, 3D spheroid culture and subcutaneous xenograft tumors propagated in mice). OHC-NB1 harbors a MYCN amplification in double minutes, 1p deletion, 17q gain and diploid karyotype, which persisted in all models. A total of 80–540 single-nucleotide variants (SNVs) was detected in each sample, and comparisons between the source metastasis and models identified 34 of 80 somatic SNVs to be propagated in the models. Clonal reconstruction using the combined copy number and SNV data revealed marked clonal heterogeneity in the originating metastasis, with four clones being reflected in the model systems. The set of OHC-NB1 models represents 43% of somatic SNVs and 23% of the cellularity in the originating metastasis with varying clonal compositions, indicating that heterogeneity is partially preserved in our model system. 相似文献
78.
目的 探讨NRP-1单克隆抗体(NRP-1 MAb)的特异性,以及不同剂量的NRP-1 MAb治疗乳腺癌裸鼠移植瘤的疗效。方法 Western blot和共聚焦免疫荧光法检测NRP-1 MAb是否识别MCF7细胞上NRP-1蛋白。将MCF7细胞接种于BALB/c裸鼠皮下建立乳腺癌细胞移植瘤模型,并进行瘤组织传代。传代的肿瘤体积生长至300~500 mm3时,随机分为对照组、NRP-1 MAb低剂量组、中剂量组和高剂量组,每组6只,给药7次。观察荷瘤裸鼠一般状况,测量瘤体大小及裸鼠体重。实验结束时剥离瘤体称重,提取组织蛋白,Western blot检测组织中VEGF蛋白和NRP-1蛋白的表达量。结果 NRP-1MAb成功识别MCF7细胞上的NRP-1蛋白;NRP-1 MAb能够有效抑制MCF7细胞裸鼠移植瘤的生长,低剂量组(1 mg/kg)抑瘤率为47.01%,中剂量组(5 mg/kg)抑瘤率为65.70%,高剂量组(10 mg/kg)抑瘤率为69.19%。。结论 NRP-1 MAb能够识别并有效结合MCF7细胞膜上的NRP-1蛋白,且可抑制MCF7细胞移植瘤的生长,NRP-1 MAb抑制移植瘤的增长可能与下调NRP-1和VEGF表达有关。 相似文献
79.
胃肠道间质瘤(gastrointestinal stromal tumor,GIST)是起源于胃肠道间叶组织的肿瘤,由于GIST存在恶性潜能,且多数GIST患者无明显临床症状,所以GIST的早期发现、诊断和治疗显得尤为重要。GIST通常在内窥镜、超声内镜(endoscopic ultrasound,EUS)检查中发现。GIST的诊断取决于形态学和免疫组织化学染色,因此组织样本的充足性是其关键。近年来,新的成像技术的应用和分子生物学的发展提高了GIST的诊断准确率,并为GIST的预后及辅助治疗提供了依据。 相似文献
80.
目前化疗仍为晚期胃癌的标准治疗手段,而多数患者诊断时已接近晚期。近年新兴的免疫治疗手段程序性死亡蛋白-1(PD-1,programmed death l)抗体,通过阻断肿瘤细胞逃避自身免疫机制,重新激活自身免疫对肿瘤的杀伤作用,从而达到肿瘤的治疗作用。针对晚期胃癌的PD-1抗体治疗的临床研究已在国内外开展,大部分均有较好效果。本文对近年免疫治疗中的PD-1抗体在晚期胃癌的重要临床研究进展进行介绍。 相似文献